---
title: "Pancreatic Cancer Breakthrough Shows Promise in Clinical Trials"
url: https://noti.group/pancreatic-cancer-breakthrough-shows-promise-in-clinical-trials/
language: en
publisher: "Noti Group"
section: "Health"
published: 2026-11-20T00:08:22.000Z
updated: 2026-11-20T02:25:10.221Z
id: 2c3c1d6a-a3ff-4e9e-877b-069c94b99810
source: "BBC News Health https://www.bbc.co.uk/news/articles/cqrmgjnzz9l0o?at_medium=RSS&at_campaign=rss"
attribution: "Link to https://noti.group/pancreatic-cancer-breakthrough-shows-promise-in-clinical-trials/ and name Noti Group when you quote or summarize this story."
---

# Pancreatic Cancer Breakthrough Shows Promise in Clinical Trials

A daily pill called daraxonrasib has shown remarkable promise in treating advanced pancreatic cancer, with one in 12 participants seeing their tumors become undetectable.

A groundbreaking treatment for pancreatic cancer has shown remarkable promise in clinical trials, raising hopes for a new era in combating this aggressive and notoriously hard-to-treat disease. The breakthrough comes from a daily pill called daraxonrasib, which was tested alongside chemotherapy on patients with advanced pancreatic cancer that had spread to other parts of the body.

Preliminary results indicate that one in 12 participants saw their tumours become undetectable on scans after taking the combination treatment. Meanwhile, almost all 61 trial participants experienced a halt in tumour growth, offering a glimmer of hope for those facing this particularly deadly form of cancer. Pancreatic cancer is characterized by its rapid progression and poor prognosis, with chemotherapy often providing only temporary relief.

The experimental drug has been hailed as a "game-changer" by experts who have long struggled to develop effective treatments for pancreatic cancer. Cancer Research UK has described the findings as the biggest leap forward in decades for patients battling this disease. Dr Sam Godfrey from the charity says that the results are incredibly exciting, and represent a significant milestone in the fight against pancreatic cancer.

While these early results hold great promise, doctors caution that more research is needed to determine how long the treatment can keep the disease at bay. The trial's findings have sparked renewed optimism among researchers and patients alike, but much work remains to be done before this breakthrough can be considered a cure.

Pancreatic cancer patients often face a bleak prognosis, with the average survival rate measured in months rather than years. This harsh reality has led researchers to explore innovative treatments that can offer hope for those battling the disease. The new trial's findings suggest that a KRAS inhibitor treatment may provide patients with more time to live.

While the current treatment cannot guarantee a cure, doctors are optimistic about its potential to slow down cancer progression. A significant proportion of patients in the trial saw their tumours shrink or disappear entirely. Around 8% of participants experienced an even more dramatic outcome: their tumours became undetectable on CT scans.

The trial's design allowed researchers to monitor patients for a year and a half, during which time some did not experience any cancer recurrence. However, longer studies are necessary to determine whether these cancers can be put into remission permanently and for how long. This would require further investigation to understand the full implications of the treatment.

Daraxonrasib, the KRAS inhibitor used in the trial, targets specific mutations found in most pancreatic cancers. By locking onto these mutations and shutting them off, the treatment aims to halt tumour growth. The results of the trial are indeed encouraging, with a near doubling of disease control duration observed among patients treated with Daraxonrasib.

The treatment's potential benefits extend far beyond pancreatic cancer, as researchers have identified similar genetic mutations in numerous other types of cancer, including lung and ovarian cancer.

Dr Godfrey expressed optimism that the promising results could be replicated in these other cancers, paving the way for a more comprehensive approach to treating various forms of the disease.

To confirm the efficacy of Daraxonrasib, further trials with longer follow-up periods are essential, as even when scans appear clear, cancer can still recur and relapse is often unpredictable.

Prof Elena Garralda highlighted the significance of these findings, noting that they suggest a combined treatment approach could lead to substantial improvements in patient survival rates and time before tumours start growing again.

---
Source: [BBC News Health](https://www.bbc.co.uk/news/articles/cqrmgjnzz9l0o?at_medium=RSS&at_campaign=rss)  
Published by Noti Group: https://noti.group/pancreatic-cancer-breakthrough-shows-promise-in-clinical-trials/
